title: Neurological course of long-term surviving patients with SCLC and anti-Hu syndrome.
abstract: Patients with small-cell lung cancer (SCLC) have a poor prognosis with a three year survival rate of 4%. Our report concerns three patients with histologically proven SCLC and anti-Hu associated paraneoplastic neurological syndrome who have survived for 11 in two cases and 16 years respectively. The patients showed progressive deterioration which was only partly beneficially modulated by steroid therapy or tumor treatment, even in the cases with complete tumor remission.
authors: University of Bonn, Department of Epileptology, Sigmund-Freud-Str. 25, Bonn, Germany. annkathrin.poepel@swissepi.ch
authors: A
authors: A
authors: Poepel
authors: S
authors: S
authors: Jarius
authors: L C
authors: LC
authors: Heukamp
authors: H
authors: H
authors: Urbach
authors: C E
authors: CE
authors: Elger
authors: C G
authors: CG
authors: Bien
authors: R
authors: R
authors: Voltz
mesh_terms: D018288:Carcinoma, Small Cell / Q000150:complications / Q000276:immunology / Q000401:mortality; D051959:ELAV Proteins / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000276:immunology / Q000401:mortality; D008297:Male; D008875:Middle Aged; D020361:Paraneoplastic Syndromes, Nervous System / Q000150:complications / Q000276:immunology / Q000401:mortality; D012189:Retrospective Studies
chemical_list: D051959:ELAV Proteins